Navigation Links
Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
Date:7/16/2008

PALO ALTO, Calif., July 16 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it has entered into definitive agreements with selected investors to sell 3,848,289 units (the "Units"), with each Unit consisting of (i) one share of the Company's common stock, par value $0.0001 per share ("Common Stock") and (ii) a warrant to purchase 0.45 of a share of Common Stock for gross proceeds of approximately $26.0 million, before deducting placement agents' fees and estimated offering expenses, in a "registered direct" offering. The Company's costs in connection with the offering are expected to be approximately $1.5 million. The investors have agreed to purchase the Units at a purchase price of $6.75625 per Unit. The warrants, which represent the right to acquire an aggregate of up to 1,731,724 shares of Common Stock, have a six year term from the date of issuance, are exercisable beginning six months after the date of issuance and will be exercisable at a price of $7.37 per share, which was 110% of the closing consolidated bid price of Jazz Pharmaceuticals' shares on the Nasdaq Global Market on July 15, 2008. The transaction is expected to close on or about July 21, 2008, subject to satisfaction of customary closing conditions. Lazard Capital Markets LLC served as lead placement agent and Leerink Swann LLC served as co-placement agent for the offering.

Jazz Pharmaceuticals intends to use the net proceeds from this offering primarily to fund commercial activities in support of Once Daily LUVOX(R) CR (fluvoxamine maleate) Extended Release Capsules, approved by the FDA in February 2008 for the treatment of both obsessive compulsive disorder and social anxiety disorder, to complete the Phase III clinical st
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... Industry leader iLab Solutions recently announced ... newly-created position, Gibbs will lead iLab’s business operations in the region, with an ... entails not only introducing iLab to potential partners but support and management of ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply ... risk management and resiliency practitioners with luminaries and thought leaders to advance the ... recognized for their innovations and performance excellence. At that time its principle sponsor, ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Mexico Biomedical Sensors market is estimated at $0.20 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapies primarily in the areas ... 30-day review period following the filing of the ... with the U.S. Food and Drug Administration (FDA) ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... , SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, ... ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, ... 20 studies at the 45th Annual Meeting of the European Association for ... 29 to Oct. 2. The companies will present the latest research findings ...
... ... million round of funding. Participating investors included CTTV Investments LLC, the venture capital ... , ... Francisco, CA (PRWEB) September 24, 2009 -- LS9, Inc., the Renewable Petroleum Company™, today ...
... , , PHILADELPHIA and LONDON, ... -- researchers likely to be in contention for Nobel honors -- in anticipation ... be announced from October 5-12. , , Thomson Reuters ... Nobel Prize winners. , , Each year, data ...
Cached Biology Technology:Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 2Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 3Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 4Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 5Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 6Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 7LS9 Secures $25 Million in Latest Round of Funding 2LS9 Secures $25 Million in Latest Round of Funding 3Thomson Reuters Predicts Nobel Laureates 2Thomson Reuters Predicts Nobel Laureates 3Thomson Reuters Predicts Nobel Laureates 4Thomson Reuters Predicts Nobel Laureates 5Thomson Reuters Predicts Nobel Laureates 6
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... it, bread that contains critical nutrients could help combat ... of a group of Johns Hopkins University undergraduate students ... so that it yields beta carotene, the orange substance ... turns into vitamin A. The students, project ...
... likely, you would be disgusted if confronted with a ... worms. Or a particularly bloody wound. Or a horribly ... disgust you feel may lend important insight into your ... scientists closely measured people,s physiological reactions as they looked ...
... -- Low levels of a brain protein that regulates gene ... disorder, a complex and sometimes disabling psychiatric disease. As reported ... journal of The International Society for Bipolar Disorders, levels of ... of the brain in postmortem samples from patients with bipolar ...
Cached Biology News:Students coax yeast cells to add vitamins to bread 2Students coax yeast cells to add vitamins to bread 3Students coax yeast cells to add vitamins to bread 4That's gross!: Study uncovers physiological nature of disgust in politics 2Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3
... Complete kit for stabilizing 1.5mg of purified ... optimised for the stabilization of aqueous RNA ... methods such as guanidine, phenol/chloroform, silica, oligo ... StabMRT Kits contain all the necessary components ...
... stabilizing 50g of purified RNA samples for RT-PCR ... all of the advantages and applications you expect ... RNA can be used for enzymatic applications such ... been optimised for the stabilization of aqueous RNA ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: